Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 8/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.48 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9458734 | 0.92 | PTGES (0.65) | PTGESALOX5PTGS1ALOX5APPTGS2 | |
| SCHEMBL6475572 | 0.88 | PTGES (0.78) | PTGESALOX5PTGS1ALOX5APPTGS2 | |
| SCHEMBL7002805 | 0.88 | PTGES (0.78) | PTGESALOX5PTGS1ALOX5APPTGS2 | |
| SCHEMBL8594214 | 0.77 | PTGES (0.74) | PTGESALOX5PTGS1KMT2A | |
| SCHEMBL6476126 | 0.76 | ALOX5 (0.47) | PTGESALOX5PTGS1PTGS2KMT2A | |
| SCHEMBL6486123 | 0.76 | PTGES (0.49) | PTGESALOX5PTGS1PTGS2KMT2A | |
| SCHEMBL6475809 | 0.76 | KMT2A (0.53) | PTGESALOX5PTGS1KMT2A | |
| Bicarbonate SCHEMBL7001311 | 0.75 | PTGES (0.52) | PTGESALOX5PTGS1ALOX5APPTGS2 | |
| SCHEMBL6476426 | 0.74 | PTGES (0.48) | PTGESALOX5PTGS1ALOX5APPTGS2 | |
| SCHEMBL7005247 | 0.74 | ALOX5 (0.46) | PTGESALOX5PTGS1PTGS2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936632-B2 | Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof | MERCKLE GMBH (DE) | 2005-08-30 | — | — | US | disclosed |
| US-20040122002-A1 | Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof | MERCKLE GMBH (DE) | 2004-06-24 | — | — | US | disclosed |
| EP-1246825-B1 | FUSED PYRROLE COMPOUNDS, PHARMACEUTICAL AGENTS CONTAINING THE SAME, AND THE USE THEREOF | MERCKLE GMBH (DE) | 2003-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122002-A1 | Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof | PTGS1, PTGS2, PTGER1 | PTGES 6/4885ALOX5 62/4885PTGS1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.